denotes an abstract that is clinically relevant.
Sponsor: SCIENTIFIC
Program: Spotlight Sessions
Sunday, December 6, 2020: 12:00 PM-12:45 PM
Panelists:
Margaret A. Shipp, MD, Dana Farber Cancer Institute
and
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Shipp: Bristol Myers Squibb: Consultancy, Research Funding; Merck: Research Funding; Celgene: Honoraria; Ono Pharmaceutical: Honoraria; Bayer: Honoraria. Perales: Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Honoraria, Research Funding; Miltenyi Biotec: Research Funding; Merck: Consultancy, Honoraria; Nektar Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees; MolMed: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Honoraria, Research Funding; Bellicum: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cidara Therapeutics: Other; Servier: Membership on an entity's Board of Directors or advisory committees, Other; NexImmune: Membership on an entity's Board of Directors or advisory committees; Medigene: Membership on an entity's Board of Directors or advisory committees, Other.
Chair:
Leslie Kean, MD, PhD, Boston Children's Hospital
Disclosures:
Kean: gilead: Research Funding; novartis: Consultancy; hifibio: Consultancy; regeneron: Research Funding; magenta: Research Funding; fortyseven: Consultancy; bluebird bio: Research Funding; kymab: Consultancy; Bristol Meyers Squibb: Research Funding.
Discussed will be the current role of allogeneic hematopoietic cell transplantation in Hodgkin Lymphoma. With the advent of novel therapies including the antibody drug conjugate brentuximab vedotin and the checkpoint inhibitors nivolumab and pembrolizumab, outcomes in patients with Hodgkin Lymphoma have continued to improve, even in patients with more high risk disease. Concomitant with this progress, the number of patients referred for allogeneic HCT has decreased. Nevertheless, recent data suggest that patients with Hodgkin Lymphoma who undergo allogeneic HCT after exposure to checkpoint inhibitors have remarkable overall survival. The discussion will review recent data for allogeneic HCT in the era of checkpoint inhibitors including sequencing of therapies, and the impact of checkpoint inhibitors on GVHD, GVL and immune-related adverse events.
See more of: Spotlight Sessions